Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors

This is a prospective, open-label, single-arm, single-center study designed to evaluate the feasibility of using patient-derived organoid drug sensitivity analysis to guide chemotherapy for pediatric patients with refractory and relapsed malignant soft tissue tumors. The primary endpoint of the study is objective response rate (ORR), and the secondary endpoint is event-free survival (EFS).

NCT Number	NCT07528079
Lead Sponsor	Shanghai Jiao Tong University School of Medicine Collaborators: Chongqing Kingbiotech Co.,Ltd
Conditions	Soft Tissue Sarcoma, Child
Enrollment	30 participants
Start Date	2026-04-01
Primary Completion	2027-08-30 (estimated)
Study Completion	2027-12-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-16